Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$50.4 million.

  • Rocket Pharmaceuticals' Free Cash Flow rose 619.28% to -$50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.8 million, marking a year-over-year decrease of 22.93%. This contributed to the annual value of -$215.6 million for FY2024, which is 200.33% down from last year.
  • Rocket Pharmaceuticals' Free Cash Flow amounted to -$50.4 million in Q3 2025, which was up 619.28% from -$49.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Free Cash Flow ranged from a high of -$24.6 million in Q1 2021 and a low of -$61.8 million during Q3 2023
  • Its 5-year average for Free Cash Flow is -$47.3 million, with a median of -$49.0 million in 2025.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 8309.15% in 2021, then soared by 4242.0% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Free Cash Flow stood at -$32.9 million in 2021, then plummeted by 79.37% to -$59.0 million in 2022, then surged by 42.42% to -$34.0 million in 2023, then crashed by 39.03% to -$47.3 million in 2024, then dropped by 6.59% to -$50.4 million in 2025.
  • Its Free Cash Flow was -$50.4 million in Q3 2025, compared to -$49.0 million in Q2 2025 and -$56.2 million in Q1 2025.